Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …

Oncology care is increasingly a multidisciplinary endeavour, and radiation therapy
continues to have a key role across the disease spectrum in nearly every cancer. However …

This review provides a comprehensive landscape of HGF/c-MET (hepatocyte growth factor
(HGF)/mesenchymal–epithelial transition factor (c-MET)) signaling pathway in cancers. First …

KRAS is a frequent oncogenic driver in solid tumors, including non-small cell lung cancer
(NSCLC). It was previously thought to be an" undruggable" target due to the lack of deep …

Thirteen new fluorine-containing drugs, which have been granted approval by the US Food
and Drug Administration (FDA) in 2020, are profiled in this review. Therapeutic areas of …

Introduction MET amplification is a rare, potentially actionable, primary oncogenic driver in
patients with NSCLC. Methods The influence of MET amplification on the clinical activity of …

Anaplastic lymphoma kinase (ALK) is a validated molecular target for non-small-cell lung
cancer (NSCLC). The use of tyrosine kinase inhibitors (TKIs) has led to significantly …

Simple Summary The treatment of advanced and metastatic non-small cell lung cancer
(NSCLC) has changed dramatically in recent years due to advanced molecular diagnostics …

Lung cancer is the second most common cancer and the leading cause of death in both men
and women in the world. Lung cancer is heterogeneous in nature and diagnosis is often at …

ALK gene rearrangement was observed in 3%–5% of non-small cell lung cancer patients,
and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used. Multiple …